Rosetta Genomics issues press release over patent allowance
On 29 January 2010, Rosetta issued a press release about allowances by the USPTO of claims in two patent applications:
The first, covering human microRNA miR-21, was derived from the “Tuschl III” patent series that is assigned to the Max Planck Society, Berlin, Germany and is used in Rosetta’s miRview™ mets and miRview™ squamous diagnostic assays. Rosetta holds a co-exclusive license to miR-21 in diagnostic applications, and a non-exclusive license for the research use field. The second patent application, covering Sanger viral hcmv-miR-UL112 and its precursor, was shown to suppress the human (host) immune system during viral infection. The allowed claims are directed to the miR, its hairpin, its complement, a DNA encoding the same, a sequence 80% identical to, a vector and a probe comprising the same.
Of Tuschl-I and -II, see previous IPBiz post
Max Planck GmbH goes after MIT, Whitehead, UMass
The first, covering human microRNA miR-21, was derived from the “Tuschl III” patent series that is assigned to the Max Planck Society, Berlin, Germany and is used in Rosetta’s miRview™ mets and miRview™ squamous diagnostic assays. Rosetta holds a co-exclusive license to miR-21 in diagnostic applications, and a non-exclusive license for the research use field. The second patent application, covering Sanger viral hcmv-miR-UL112 and its precursor, was shown to suppress the human (host) immune system during viral infection. The allowed claims are directed to the miR, its hairpin, its complement, a DNA encoding the same, a sequence 80% identical to, a vector and a probe comprising the same.
Of Tuschl-I and -II, see previous IPBiz post
Max Planck GmbH goes after MIT, Whitehead, UMass
posted by Lawrence B. Ebert at 11:55 AM
0 Comments:
Post a Comment
<< Home